Subsequently, landmark clinical trials demonstrated that combining fecal microbiota transplantation (FMT) from ICI responders with anti-PD-1 therapy overcomes PD-1 blockade resistance in melanoma patients (Baruch et al., 2021). The gene discussed is PDCD1; the disease is melanoma.